LOGIN  |  REGISTER
Viking Therapeutics
Viking Therapeutics

Ardent Health to Participate in May Investor Conferences

May 05, 2025 | Last Trade: US$14.59 0.09 0.62

BRENTWOOD, Tenn. / May 05, 2025 / Business Wire / Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that members of the Company's management team will participate in the following upcoming investor conferences:

  • Bank of America Securities 2025 Health Care Conference on May 13 and 14, 2025, in Las Vegas, Nevada. Members of the management team will participate in a presentation at 11:40 a.m. ET on Wednesday, May 14, 2025.
  • 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20, 2025, in New York City, New York. Members of the management team will participate in a fireside chat at 8:00 a.m. ET that same day.

A live audio webcast of these presentations will be available in the Investor Relations section of the Company’s website, at ir.ardenthealth.com, and a replay will be available for 90 days using the same link.

In conjunction with these conferences, the Ardent Health management team will be available to participate in one-on-one meetings with investors registered to attend each conference. For more information, please contact your sales representative at the host firm, or Dave Styblo, Ardent Health’s senior vice president of investor relations at This email address is being protected from spambots. You need JavaScript enabled to view it..

About Ardent Health

Ardent Health (NYSE: ARDT) is a leading provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in innovative services and technologies, Ardent is passionate about making healthcare better and easier to access. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and 280 sites of care with over 1,800 affiliated providers across six states. For more information, please visit ardenthealth.com.

Chimerix

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page